October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6-month results of the REBALANCE-HF randomized, blinded feasibility trial of the Splanchnic Ablation for Volume Management (SAVM) procedure for heart failure with preserved ejection fraction (HFpEF). The main objectives of the feasibility study were to demonstrate safety, evaluate the ease and repeatable nature of the procedure, and identify the subtype of patients most likely to respond to the therapy to inform future clinical trials. While there was no improvement with the SAVM procedure compared to a control sham procedure in the full study cohort, preliminary results identified HFpEF patients who are sensitive to acute shifts in blood volume during exercise or stress were more likely to be responsive to SAVM. The responder group, which made up more than half of the full cohort, saw clinically meaningful improvements in functional capacity, symptoms and quality of life